MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, ...
The applicants say the plant would generate enough electricity to supply about 78,018 local households annually. | ITV News ...
FDA grants Priority Review and assigns a PDUFA goal date of July 17, 2026MINNEAPOLIS, (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: ...
Ranchi: The Jharkhand Academic Council (JAC) extended the last date for submission of application forms for the Akanksha-40 entrance examination to Ja.
Step 1: Click the NDA & NA I 2026 notice link at upsc.gov.in. Step 2: Select the online application gateway and navigate to upsconline.nic.in. Step 3: Enter the necessary contact and personal ...
OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif. Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the ...
The FDA has accepted a New Drug Application (NDA) for Celcuity’s gedatolisib in hormone receptor positive (HR+), human ...
LOR is the first drug candidate with disease-modifying potential for osteoarthritis submitted for approval, demonstrating statistically and clinically significant improvements in pain, function and ...
HONG KONG, Jan. 19, 2026 /PRNewswire/ -- (9926.HK) announced that its supplemental New Drug Application (sNDA) for gumokimab (AK111), a novel humanized anti-IL-17A monoclonal antibody for the treatmen ...
LOS ALTOS, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced ...
(BUSINESS WIRE )--Takeda (TSE:4502/NYSE:TAK ) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug ...
NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback